Corbion stock gains as ABN AMRO lifts price target to EUR 26

Published on 09/10/2026 at 19:52 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Corbion stock climbed after ABN AMRO raised its price target to EUR 26 on September 10, 2026, citing higher EBITDA and EPS forecasts. The shares recently traded near EUR 22.62 on Euronext Amsterdam, helped by improving margin expectations.

Isometrische 3D-Grafik von Rohstoffen, Fermentationstanks und verpackten Ingredienzien — Isometrische 3D-Illustration der Wertschöpfungskette veranschaulicht den Produktionsprozess von Corbion N.V. (ISIN NL0010583399), Illustration mit AI erstellt.

Corbion NV stock (ISIN NL0010583399) attracted renewed interest after ABN AMRO raised its price target from EUR 23.00 to EUR 26.00 on September 10, 2026, while reiterating an Outperform rating on the Dutch ingredients specialist. According to Beleggen.nl on September 10, 2026, the bank sees upside from stronger medium-term profitability, and the stock reacted with a single-day gain of 4.3 percent to EUR 22.62 on Euronext Amsterdam.

ABN AMRO sharpens its Corbion view

ABN AMRO’s revised analysis places the new EUR 26.00 price target roughly 13 percent above the prior EUR 23.00 level, signaling more constructive expectations for Corbion’s earnings power. According to Beleggen.nl on September 10, 2026, the bank lifted its forecasts for adjusted EBITDA in 2027 and 2028 by about 6 and 8 percent respectively, which in turn supports increases of 10 and 13 percent in projected earnings per share for those years. The analyst team left its expectations for 2026 broadly unchanged, framing the stronger out-years as driven by efficiency gains and mix improvements rather than a one-off boost.

The margin trajectory is central to ABN AMRO’s thesis. As reported by Beleggen.nl, the bank expects Corbion’s adjusted EBITDA margin to rise from 16.0 percent in 2026 to 17.4 percent in 2027 and further to 18.2 percent in 2028, a cumulative gain of 2.2 percentage points over the period. For investors, that gradual but concrete margin expansion is a key part of the story, because it implies that future revenue growth could translate more directly into bottom-line improvement.

Share price reaction and valuation context

ABN AMRO’s call did not go unnoticed in the market. According to the same analysis on Beleggen.nl, Corbion stock rose 4.3 percent to EUR 22.62 in trading on September 10, 2026, following the price-target increase, bringing the shares closer to, yet still below, the new EUR 26.00 target. In percentage terms, the closing level of EUR 22.62 is about 13 percent below the bank’s valuation view, which underlines the perceived upside without suggesting extreme exuberance.

ABN AMRO also highlighted that at EUR 26.00 per share Corbion would still be valued significantly below sector peers and its own historical multiples. As summarized by Beleggen.nl, the bank sees the stock as noticeably cheaper than comparable food ingredients and biotech names even after the recent move. For investors, this relative valuation argument is important because it suggests that both margin expansion and a re-rating could contribute to the potential total return.

Strategic backdrop and product news

The analyst upgrade comes against a backdrop of operational and strategic developments at Corbion. The company has been working to refine its portfolio, including an ongoing process to divest its polylactic acid activities, which sector commentators note has been on investors’ watch lists for some time. A premium analysis on Beursduivel in early September 2026 described how a major shareholder, Inclusive Capital, exited its stake around EUR 20 earlier in the summer, reducing technical selling pressure and allowing fundamental drivers to play a larger role in the share price.

At the same time, Corbion continues to invest in its core ingredient platforms. On September 10, 2026, the company announced an expansion of its natural mold inhibition portfolio with Verdad Essence WH150, a cultured wheat solution aimed at helping bakers achieve reliable mold-free shelf life while maintaining product quality. As Perishable News reported on September 10, 2026, Verdad Essence WH150 is positioned as a clean-label cultured wheat alternative designed to extend shelf life without compromising sensory properties. For a company whose growth story relies heavily on specialty food ingredients and preservation technologies, such product launches help underpin the earnings forecasts behind ABN AMRO’s raised targets.

Recent price levels and investor perspective

Before the latest analyst action, Corbion shares had been trading in a relatively neutral corridor. A market wrap noted that Corbion stock closed at around EUR 25.00 on Euronext Amsterdam on September 6, 2026, with the daily move described as broadly flat versus the prior session and the price near the middle of its recent trading range. This overview, published on September 10, 2026, highlighted that the Euronext Amsterdam closing level left the stock roughly in the middle of its observed range for the current period, offering a reference point for investors assessing subsequent moves.

For shareholders, the combination of a concrete price-target increase, quantified EPS and EBITDA upgrades and visible margin expansion creates a clearer medium-term narrative than the more volatile trading seen earlier in the year. The outperformance assumption rests not only on internal efficiency, but also on Corbion’s ability to commercialize innovations like Verdad Essence WH150 in attractive end markets such as bakery preservation. If the company can deliver on the 16.0 percent to 18.2 percent adjusted EBITDA margin path between 2026 and 2028 reported by ABN AMRO, the gap between the current share price and the EUR 26.00 target may narrow.

Corbion stock on Euronext Amsterdam

Corbion stock is listed on Euronext Amsterdam, where it recently closed at EUR 22.62 after the ABN AMRO price-target revision on September 10, 2026, compared with around EUR 25.00 at the Euronext close on September 6, 2026. That shift places the shares modestly below the new EUR 26.00 target and highlights how analyst calls and product developments can interact to shape price expectations over time. For investors, the key checkpoints now include the next set of quarterly results and any update on portfolio transactions, which will show how quickly the projected margin gains start to materialize in reported numbers.